BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 18492693)

  • 1. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
    Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC
    Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice.
    Jenkins DE; Hornig YS; Oei Y; Dusich J; Purchio T
    Breast Cancer Res; 2005; 7(4):R444-54. PubMed ID: 15987449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
    Mitsiades CS; Mitsiades NS; Bronson RT; Chauhan D; Munshi N; Treon SP; Maxwell CA; Pilarski L; Hideshima T; Hoffman RM; Anderson KC
    Cancer Res; 2003 Oct; 63(20):6689-96. PubMed ID: 14583463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma.
    Alici E; Konstantinidis KV; Aints A; Dilber MS; Abedi-Valugerdi M
    Exp Hematol; 2004 Nov; 32(11):1064-72. PubMed ID: 15539084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current role of immunotherapy in multiple myeloma.
    Hájek R; Adam Z; Krivanová A; Doubek M; Korístek Z; Vorlícek J
    Acta Med Austriaca; 1998; 25(3):79-85. PubMed ID: 9816399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
    Hoffman RM
    Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
    Kröger N; Zagrivnaja M; Schwartz S; Badbaran A; Zabelina T; Lioznov M; Ayuk F; Zander A; Fehse B
    Exp Hematol; 2006 May; 34(5):688-94. PubMed ID: 16647575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body bioluminescent imaging of human uveal melanoma in a new mouse model of local tumor growth and metastasis.
    Notting IC; Buijs JT; Que I; Mintardjo RE; van der Horst G; Karperien M; Missotten GS; Jager MJ; Schalij-Delfos NE; Keunen JE; van der Pluijm G
    Invest Ophthalmol Vis Sci; 2005 May; 46(5):1581-7. PubMed ID: 15851554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel bioluminescent tumor model of human renal cancer cell lines: an in vitro and in vivo characterization.
    Peter C; Kielstein JT; Clarke-Katzenberg R; Adams MC; Pitsiouni M; Kambham N; Karimi MA; Kengatharan KM; Cooke JP
    J Urol; 2007 Jun; 177(6):2342-6. PubMed ID: 17509355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in multiple myeloma--possibility or probability?
    Harrison SJ; Cook G
    Br J Haematol; 2005 Aug; 130(3):344-62. PubMed ID: 16042684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis.
    van der Horst G; van Asten JJ; Figdor A; van den Hoogen C; Cheung H; Bevers RF; Pelger RC; van der Pluijm G
    Eur Urol; 2011 Aug; 60(2):337-43. PubMed ID: 21616583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive visualization of retinoblastoma growth and metastasis via bioluminescence imaging.
    Ji X; Cheng L; Wei F; Li H; Wang M; Tian Y; Chen X; Wang Y; Wolf F; Li C; Huang Q
    Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5544-51. PubMed ID: 19608529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.
    Campbell RA; Manyak SJ; Yang HH; Sjak-Shie NN; Chen H; Gui D; Popoviciu L; Wang C; Gordon M; Pang S; Bonavida B; Said J; Berenson JR
    Int J Oncol; 2006 Jun; 28(6):1409-17. PubMed ID: 16685443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality.
    van Rijn RS; Simonetti ER; Hagenbeek A; Bonyhadi M; Storm G; Martens AC; Ebeling SB
    Exp Hematol; 2007 Jan; 35(1):117-27. PubMed ID: 17198880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation.
    Voena C; Malnati M; Majolino I; Fagà G; Montefusco V; Farina L; Santoro A; Ladetto M; Boccadoro M; Corradini P
    Bone Marrow Transplant; 2003 Oct; 32(8):791-3. PubMed ID: 14520423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bioluminescent mouse model of pancreatic {beta}-cell carcinogenesis.
    Zumsteg A; Strittmatter K; Klewe-Nebenius D; Antoniadis H; Christofori G
    Carcinogenesis; 2010 Aug; 31(8):1465-74. PubMed ID: 20530553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the biology of multiple myeloma: therapeutic applications.
    Anderson K
    Semin Oncol; 1999 Oct; 26(5 Suppl 13):10-22. PubMed ID: 10528890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model.
    Ashihara E; Kawata E; Nakagawa Y; Shimazaski C; Kuroda J; Taniguchi K; Uchiyama H; Tanaka R; Yokota A; Takeuchi M; Kamitsuji Y; Inaba T; Taniwaki M; Kimura S; Maekawa T
    Clin Cancer Res; 2009 Apr; 15(8):2731-8. PubMed ID: 19351774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.
    Chiriva-Internati M; Cobos E; Kast WM
    Int Rev Immunol; 2007; 26(3-4):197-222. PubMed ID: 17558744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment.
    Sekimoto E; Ozaki S; Ohshima T; Shibata H; Hashimoto T; Abe M; Kimura N; Hattori K; Kawai S; Kinoshita Y; Yamada-Okabe H; Tsuchiya M; Matsumoto T
    Cancer Res; 2007 Feb; 67(3):1184-92. PubMed ID: 17283154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.